David J. Grainger - Sep 30, 2022 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role
Chief Innovation Officer
Signature
/s/ Gregory Weinhoff, attorney-in-fact
Stock symbol
CNTA
Transactions as of
Sep 30, 2022
Transactions value $
-$30,405
Form type
4
Date filed
1/13/2023, 04:46 PM
Previous filing
Jul 6, 2022
Next filing
Jan 4, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CNTA Ordinary Shares Tax liability -$30.4K -7.15K -0.78% $4.25 907K Sep 30, 2022 Direct F1, F2, F3, F4
holding CNTA Ordinary Shares 27.5K Sep 30, 2022 See footnote F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units.
F3 Shares held by the Reporting Person after the reported transaction herein and does not include shares acquired or disposed of in subsequent reported transactions after September 30, 2022.
F4 As of year end December 31, 2022, the Reporting Person held 904,105 shares directly.
F5 Held by RxCelerate Limited ("RxCelerate"). The Reporting Person is a member of the board of directors of RxCelerate. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by RxCelerate, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.